ArticleTranslational cancer research2026
Fibulin-5 (FBLN5) as a context-dependent pan-cancer regulator: integrated multi-omics analysis reveals dual roles in tumor progression and therapeutic resistance.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fibulin-5 (FBLN5) is a key member of the extracellular matrix (ECM), which plays an important role in the occurrence and development of tumors. This study aimed to determine the role of FBLN5 in the diagnosis, prognosis, and immune regulation of tumors using a pan-cancer analysis. Methods: By integrating and analyzing data from multiple public databases, including The Cancer Genome Atlas (TCGA), Firehose, University of California, Santa Cruz (UCSC) Xena, cBioPortal, Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Tumor Immune Estimation Resource 2.0 (TIMER2.0), Tumor Immune Single-cell Hub (TISCH), CellMiner, Genomics of Drug Sensitivity in Cancer (GDSC), and Cancer Therapeutics Response Portal (CTRP), we comprehensively investigated the diagnostic and prognostic potential of FBLN5 across multiple types. We further performed a gene set enrichment analysis (GSEA) to elucidate the biological functions associated with FBLN5 expression. Additionally, a survival analysis was conducted to assess its prognostic value, and genetic alteration, methylation, and pathway analyses were also performed. Finally, we examined the relationship between FBLN5 and immunity response, and identified potential drugs that may affect the efficacy of tumor treatment. Results: The analysis of TCGA data revealed that FBLN5 RNA was differentially expressed across multiple tumor types, and in 92% of tumor types, the expression level of FBLN5 protein is lower. Genetic and epigenetic alterations-including mutations, somatic copy number alterations, and DNA methylation-were associated with its dysregulated expression. FBLN5 expression was also correlated with several key clinical features. Further, functional analyses linked FBLN5 expression to various metabolism-, metastasis-, and immune-related pathways. Elevated FBLN5 expression had a controversial effect on prognosis across multiple tumors, and influenced sensitivity to numerous therapeutic agents. Additionally, FBLN5 expression showed significant correlations with immunoregulatory molecules and biomarkers indicative of lymphocyte subpopulation infiltration. Conclusions: This study conducted a systematic analysis of FBLN5 and its regulatory network, demonstrating that FBLN5 expression is closely associated with DNA methylation and drug resistance across multiple tumor types. Further, FBLN5 was found to remodel the tumor microenvironment and cause resistance to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.